Payment overview · 2025
General Payments
$72.51
2 reported records · 2 companies
Healthcare provider profile · identity verified
Paul B. Moore, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · AUSTIN, TX · NPI 1114986999
Verified facts
What the public records show
CMS Open Payments records show Paul B. Moore, MD received $72.51 in general payments during 2025 across 2 reported records.
Dexcom, Inc. accounted for 68.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $49.88 | 68.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.63 | 31.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $72.51 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $49.88 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 850 | 246 |
| Ozempic | Semaglutide | 443 | 81 |
| Metformin Hcl Er | Metformin Hcl | 359 | 115 |
| Atorvastatin Calcium | Atorvastatin Calcium | 331 | 109 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 285 | 85 |
| Mounjaro | Tirzepatide | 254 | 43 |
| Jardiance | Empagliflozin | 243 | 67 |
| Lisinopril | Lisinopril | 211 | 64 |
| Synthroid | Levothyroxine Sodium | 185 | 54 |
| Metformin Hcl | Metformin Hcl | 174 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 55 |
| Simvastatin | Simvastatin | 122 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 115 | 35 |
| Humalog Kwikpen U-100 | Insulin Lispro | 115 | 40 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 98 | 42 |
| Glimepiride | Glimepiride | 95 | 30 |
| Novolog Flexpen | Insulin Aspart | 93 | 33 |
| Losartan Potassium | Losartan Potassium | 87 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 26 |
| Tradjenta | Linagliptin | 85 | 26 |
| Gabapentin | Gabapentin | 80 | 25 |
| Trulicity | Dulaglutide | 73 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 63 | 18 |
| Januvia | Sitagliptin Phosphate | 60 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | 18 |
| Hydrocortisone | Hydrocortisone | 54 | 14 |
| Novolog | Insulin Aspart | 54 | 20 |
| Glipizide Er | Glipizide | 50 | 19 |
| Farxiga | Dapagliflozin Propanediol | 49 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 49 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | 14 |
| Ezetimibe | Ezetimibe | 44 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 44 | 20 |
| Alendronate Sodium | Alendronate Sodium | 42 | 15 |
| Humalog | Insulin Lispro | 41 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 40 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 13 |
| Cabergoline | Cabergoline | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 37 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 15 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 35 | suppressed |
| Testosterone | Testosterone | 34 | 12 |
| Incontrol Pen Needle | Pen Needle, Diabetic | 33 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | 15 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 31 | 11 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Teriparatide | Teriparatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $72.51 · 2 records | Dexcom, Inc. | Dexcom G6 Transmitter, TZIELD | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with SANOFI-AVENTIS U.S. LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error